Crizotinib resistance conferred by BRAF V600E mutation in non–small cell lung cancer harboring an oncogenic ROS1 fusion

Sehgal, 2018, Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors, Transl. Cancer Res., 7, S779, 10.21037/tcr.2018.08.11 D'Angelo, 2020, Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies, Cancers (Basel), 12 Watanabe, 2018, Appearance of a BRAF mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion, J. Thorac. Oncol., 13, e66, 10.1016/j.jtho.2017.11.125 Shaw, 2019, Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001, Ann. Oncol., 30, 1121, 10.1093/annonc/mdz131 Meng, 2020, Combined osimertinib, daBRAFenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation, Lung Cancer, 146, 358, 10.1016/j.lungcan.2020.05.036